Biocorp Production (ALCOR.PA) Stock Price
Biocorp Production Price
Over the last 10 years Biocorp Production grew revenue by 19.1% annually, reaching 11.67 M EUR. Earnings per share have grown at 81.2% per year over the last 7 years. For Biocorp Production, the net margin of -5.6% is up versus -136.4% a few years ago.
Biocorp Production stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Biocorp Production over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Biocorp Production stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Biocorp Production's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Biocorp Production Price |
|---|
Biocorp Production Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Biocorp Production Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM EUR |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM EUR |
| EBITM EUR |
| EBIT MARGIN% |
| NET INCOMEM EUR |
| NET INCOME GROWTH% |
| SHARESM |
| 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023e | 2024e | 2025e | 2026e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.00 | 2.00 | 1.00 | 2.00 | 2.00 | 2.00 | 3.00 | 8.00 | 8.00 | 10.00 | 11.00 | 14.00 | 22.00 | 29.00 | 61.00 |
| – | – | -50.00 | 100.00 | – | – | 50.00 | 166.67 | – | 25.00 | 10.00 | 27.27 | 57.14 | 31.82 | 110.34 |
| 250.00 | 250.00 | 500.00 | 250.00 | 250.00 | 250.00 | 166.67 | 62.50 | 37.50 | 50.00 | 45.45 | 45.45 | 45.45 | 45.45 | 45.45 |
| 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 3.00 | 5.00 | 5.00 | 6.36 | 10.00 | 13.18 | 27.73 |
| – | -1.00 | -2.00 | -2.00 | -4.00 | -7.00 | -5.00 | – | -1.00 | – | – | – | 2.00 | 4.00 | 49.00 |
| – | -50.00 | -200.00 | -100.00 | -200.00 | -350.00 | -166.67 | – | -12.50 | – | – | – | 9.09 | 13.79 | 80.33 |
| – | – | – | – | -4.00 | -7.00 | -5.00 | – | -1.00 | – | – | – | 1.00 | 3.00 | 52.00 |
| – | – | – | – | – | 75.00 | -28.57 | – | – | – | – | – | – | 200.00 | 1,633.33 |
| 2.00 | 2.00 | 2.96 | 3.38 | 3.39 | 4.03 | 4.15 | 4.13 | 4.35 | 4.35 | 4.40 | 4.40 | 4.40 | 4.40 | 4.40 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Biocorp Production generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Biocorp Production retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Biocorp Production's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Biocorp Production has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Biocorp Production's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Biocorp Production stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Biocorp Production Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Biocorp Production business model & stock analysis
Biocorp Production SWOT Analysis
Strengths
Biocorp Production SA holds a strong position in the market due to its advanced technological capabilities and innovative product offerings. The company benefits from an experienced and skilled workforce that consistently delivers high-quality biotechnology solutions. Additionally, Biocorp Production SA has established strong relationships with key partners and customers, enabling them to maintain a competitive edge.
Weaknesses
Despite its numerous strengths, Biocorp Production SA faces certain weaknesses. One of these weaknesses is its limited production capacity, which may restrict its ability to meet increasing market demand. Additionally, the company heavily relies on a few major customers, making it vulnerable to their changes in demand or potential loss of business. Biocorp Production SA also struggles with relatively limited brand recognition compared to some of its larger competitors.
Opportunities
Biocorp Production SA has several opportunities to capitalize on. The growing demand for biotechnology solutions presents a favorable market environment for the company to expand its customer base and increase sales. Furthermore, emerging partnerships and collaborations with research institutions or pharmaceutical companies can open doors for valuable synergies and the development of new products. Biocorp Production SA can also explore untapped markets or geographical regions to further enhance growth and market penetration.
Threats
Biocorp Production SA faces a range of threats that could impact its business. Intense competition within the biotechnology industry, characterized by the presence of larger and more established players, poses a challenge for the company. Rapidly evolving market trends and technological advancements can also pose a threat if Biocorp Production SA fails to adapt swiftly. Additionally, regulatory changes or stricter compliance requirements may impact the company's operations and increase costs.
Biocorp Production Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Biocorp Production historical P/E ratio, EBIT multiple, and P/S ratio
Biocorp Production annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Biocorp Production shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Biocorp Production shareholder structure
| % | Name |
|---|---|
2.79116% | |
1.25040% | |
0.70477% | |
0.69956% | |
0.64446% | |
0.24553% |
Biocorp Production Beneficial Ownership Filings (SEC 13D/G)
Biocorp Production Executives and Management Board
12 members · 17 % women
Management
Mr. Eric Dessertenne
Chief Executive Officer
Board of Directors
Mr. Jacques Gardette
Chairman of the Board · since 2015
Mr. Stephane Chabanais
Administrative and financial director
Ms. Alexia Garin
Regulatory Quality Director
Mr. Thierry Guillemaut
Production Director · since 2018
Mr. Arnaud Guillet
Business Development Director
Mr. Xavier Julia
Industrialization Director of Connected Products
Frequently asked questions about Biocorp Production
The business model of Biocorp Production SA is centered around the development and manufacturing of innovative medical devices and drug delivery systems. As a leading company in the pharmaceutical industry, Biocorp focuses on providing customized solutions to its clients, such as pharmaceutical companies and healthcare organizations, to enhance patient care and treatment outcomes. Through its cutting-edge technologies and expertise in connected devices, Biocorp aims to improve medication adherence, enable patient monitoring, and streamline the administration of drugs. By offering reliable and user-friendly solutions, Biocorp Production SA aims to establish itself as a trusted provider in the healthcare market.
Biocorp Production SA is primarily active in the pharmaceutical and healthcare industries.
The main competitors of Biocorp Production SA in the market include companies such as XYZ Pharmaceuticals, ABC Biotech, and DEF Healthcare.
Biocorp Production SA, a leading company in the field of medical devices, has a rich history and background. Established in 2004, Biocorp has been dedicated to developing and manufacturing innovative solutions for drug delivery and patient monitoring. The company focuses on integrating connectivity and customization into its products, catering to the evolving needs of healthcare professionals and patients. With a commitment to quality and technological advancements, Biocorp has gained a strong presence in the global healthcare market. Its expertise in connected devices and partnerships with major pharmaceutical companies have further positioned Biocorp as a reliable and trusted provider in the industry.
Biocorp Production SA, a leading stock company, has achieved remarkable milestones in its journey. The company has successfully expanded its product portfolio and entered into strategic partnerships, broadening its market presence. With a focus on innovation, Biocorp has introduced groundbreaking technologies and solutions that have revolutionized the industry. They have also demonstrated consistent financial growth and maintained a strong position in the market. Biocorp Production SA's commitment to quality, customer satisfaction, and sustainability has earned them numerous accolades and recognition within the sector. Through their continuous efforts, Biocorp remains dedicated to driving success and delivering value to its shareholders.
Biocorp Production SA is primarily present in several countries and regions worldwide. As a leading company in the biotechnology industry, Biocorp Production SA has established its presence in key markets. Currently, the company operates in multiple countries and regions, including Europe, North America, Asia-Pacific, and Latin America. With its global footprint, Biocorp Production SA has successfully expanded its operations and collaborations to maximize its market reach and serve a diverse customer base.
Biocorp Production SA represents values of innovation, quality, and sustainability. The company's corporate philosophy focuses on developing cutting-edge technologies and solutions in the pharmaceutical and medical industries. Biocorp is committed to improving patient care and treatment through its advanced drug delivery systems and connected devices. With a strong emphasis on research and development, Biocorp strives to provide reliable and user-friendly products that enhance patient outcomes. By integrating technology and healthcare, Biocorp Production SA aims to revolutionize the industry and contribute to a healthier future.
10 analysts currently rate the Biocorp Production stock: 8 recommend buying, 2 holding and 0 selling.
The Biocorp Production share (ALCOR.PA) is listed on 4 stock exchanges, including: Frankfurt (8BP.F), München (8BP.MU), Paris (ALCOR.PA).
Biocorp Production SA is a company specializing in the manufacture and marketing of products in the field of biotechnology. The company is based in Issoire, France and was founded in 2004. With its expertise and the use of state-of-the-art technologies, the company develops and produces high-quality products in the areas of drug delivery and diagnostics. The main focus is on the development and production of smart drug delivery systems such as Smart Insulin Pens. Under the brand Enject, the company offers a variety of insulin pens that allow for effective, safe, and easy administration of insulin in diabetic patients. The pens can be customized to meet the needs of each individual patient. Another core area of the company is the development of diagnostic systems. Biocorp Production SA offers a diagnostic device called Mallya, which specializes in measuring blood glucose and uric acid levels. The device is easy to use and allows patients to quickly and accurately monitor their blood glucose levels without time-consuming doctor visits. In addition to developing and manufacturing its own products, Biocorp Production SA also collaborates with other companies to develop customized solutions for their specific needs. For example, products such as the insulin pen have been produced for a well-known pharmaceutical company. As a technology company, research and development play an important role in the business of Biocorp Production SA. The company holds several patents on smart injection systems and diagnostic technologies and continuously invests in the development of technologies that bring maximum benefits to its customers and their patients. The company operates internationally and serves both the European and North American markets. It has experienced rapid expansion in recent years and plans to expand its presence in other parts of the world. Overall, Biocorp Production SA offers a wide range of innovative products and services in the field of biotechnology. The company focuses on the development of smart drug delivery systems and diagnostic devices, utilizing state-of-the-art technologies and working closely with other companies to develop customized solutions for its customers.
The revenue cannot currently be calculated for Biocorp Production.
The profit cannot currently be calculated for Biocorp Production.
The P/E ratio cannot be calculated for Biocorp Production at the moment.
The P/S cannot be calculated for Biocorp Production currently.
The Eulerpool Quality Score for Biocorp Production is 3/10.
The ISIN of Biocorp Production is FR0012788065. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Biocorp Production is A14V4G. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Biocorp Production is ALCOR.PA. The ticker symbol is used to trade Biocorp Production shares on the stock exchange.
Biocorp Production is assigned to the 'Health' sector.
The dividends of Biocorp Production are distributed in EUR.
Biocorp Production stock
Biocorp Production Peer Group
Biocorp Production Ticker
Biocorp Production FIGI
All fundamentals and in-depth analysis of Biocorp Production
Our stock analysis for Biocorp Production stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Biocorp Production. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.